In a move aimed at accelerating clinical translation, Windward Bio and other investors continue to back modality-led startups—while Latus Bio’s series A supports gene therapy candidates selected for early clinical data generation. Separately, the genomics and cell-engagement landscape continues to attract capital tied to clear milestone-driven development plans rather than platform-only bets.